Nemolizumab was developed as an inhibitor of IL-31 signaling, and several studies have presented findings that indicated a direct effect of IL-31 in the generation of pruritus in patients with atopic dermatitis (14, 15, 30, 31). Here, IL31 is linked to atopic eczema.